Suchergebnisse - "Kreutzfeldt, Simon"

PubPharm (54)

11

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity

enthalten in: Nature communications | 2022

von Möhrmann, L. | Werner, M. | Oleś, M. | +41

12

Assigning evidence to actionability : An introduction to variant interpretation in precision cancer medicine

enthalten in: Genes, chromosomes & cancer | 2022

von Horak, P. | Leichsenring, J. | Goldschmid, H. | +21

13

Author Correction : The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

enthalten in: Nature cancer | 2022

von Tamborero, D. | Dienstmann, R. | Rachid, M. | +79

ErratumFor: Nat Cancer. 2022 Feb;3(2):251-261. - PMID 35221333

14

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity) : Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

enthalten in: Genetics in medicine : official journal of the American College of Medical Genetics | 2022

von Horak, P. | Griffith, M. | Danos, A. | +44

CommentIn: Genet Med. 2022 Sep;24(9):1986-1988. - PMID 35779071

15

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity) : joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

enthalten in: Genetics in medicine | 29 January 2022

von Horak, P. | Griffith, M. | Danos, A. | +44

16

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

enthalten in: Nature cancer | 2022

von Tamborero, D. | Dienstmann, R. | Rachid, M. | +79

ErratumIn: Nat Cancer. 2022 May;3(5):649. - PMID 35449310

17

Gene expression-based prediction of pazopanib efficacy in sarcoma

enthalten in: European journal of cancer | 25 June 2022

von Heilig, C. | Laßmann, A. | Mughal, S. | +44

18

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

enthalten in: Annals of oncology | 18 August 2022

von Jahn, A. | Rump, A. | Widmann, T. | +75

19

Assigning evidence to actionability : An introduction to variant interpretation in precision cancer medicine

enthalten in: Genes, Chromosomes and Cancer | 2022

von Horak, P. | Leichsenring, J. | Goldschmid, H. | +21

20

Bcl‐x L as prognostic marker and potential therapeutic target in cholangiocarcinoma

enthalten in: Liver International | 2022

von Hoffmeister‐Wittmann, P. | Mock, A. | Nichetti, F. | +45